Malignant giant cell tumor of soft parts

Dodd, Leslie G.; Major, Nancy M.; Brigman, Brian E.

doi:10.1007/s00256-003-0744-8

Cited by 30 publications

(35 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the MR findings are not consistant with an aneurymal bone cyst. Giant cell tumor of soft tissue in a superficial location has a relatively lower incidence of metastases than deeply located soft tissue lesions [10], although malignant giant cell tumor of soft tissue in a superficial location has been reported [15]. Therefore, a long follow-up period is recommended.…”

Section: Discussionmentioning

confidence: 98%

Giant cell tumor of soft tissue: a case report with emphasis on MR imaging

et al. 2015

View full text Add to dashboard Cite

Giant cell tumor of soft tissue is a rare neoplasm, histologically resembling giant cell tumor of bone. In this report, we describe a deep and solid giant cell tumor of soft tissue interpreted as a benign soft tissue tumor based on magnetic resonance (MR) findings with hypointense to intermediate signals on T2-weighted images and impeded diffusivity (water movement) on diffusion-weighted imaging (DWI), which could suggest a giant-cell-containing benign soft tissue tumor, despite the malignancy suggested by 18F-fluorodeoxyglucose positron emission tomography-computed tomography in a 35-year-old male. To our knowledge, this report introduces the first deep, solid giant cell tumor of soft tissue with MR features of a giant-cell-containing benign soft tissue tumor, despite the malignancy-mimicking findings on 18F-FDG PET-CT.

show abstract

Section: Discussionmentioning

confidence: 98%

Giant cell tumor of soft tissue: a case report with emphasis on MR imaging

et al. 2015

View full text Add to dashboard Cite

show abstract

“…While usually benign, GCT is locally aggressive and most commonly occurs in the epiphysis of long bones. GCT of soft parts are very rare, but have been described [25,26], as have GCT of the thyroid [27] and pancreas [28,29].…”

Section: Resultsmentioning

confidence: 99%

Giant cell tumor of the uterus: case report and response to chemotherapy

Skubitz

Manivel

2007

BMC Cancer

View full text Add to dashboard Cite

Background: Giant cell tumor (GCT) is usually a benign but locally aggressive primary bone neoplasm in which monocytic macrophage/osteoclast precursor cells and multinucleated osteoclast-like giant cells infiltrate the tumor. The etiology of GCT is unknown, however the tumor cells of GCT have been reported to produce chemoattractants that can attract osteoclasts and osteoclast precursors. Rarely, GCT can originate at extraosseous sites. More rarely, GCT may exhibit a much more aggressive phenotype. The role of chemotherapy in metastatic GCT is not well defined.

show abstract

“…2,[5][6][7] Current theories suggest that GCTSP may be a variant of histiocytic sarcoma. 1,4,6 Previous ultrastructural examinations also suggest a mesenchymal origin. 2 The current report documents a series of 21 cases of equine GCTSP clinically evaluated in the state of Colorado from 2000 to 2007, with partial characterization of immunohistochemistry.…”

mentioning

confidence: 99%

“…4 The most common location in humans is on the limbs. 1 In human cases, immunohistochemistry is often positive for vimentin, CD68, and tartrate-resistant acid phosphatase (TRAP), with occasional positivity for cytokeratin and smooth-muscle actin. 4 Such tumors are typically negative for CD31, desmin, CD45, and lysozyme.…”

mentioning

confidence: 99%

Equine Giant Cell Tumor of Soft Parts: A Series of 21 Cases (2000–2007)

Bush

Powers

2008

J VET Diagn Invest

View full text Add to dashboard Cite

Abstract. In horses, giant-cell tumors of soft parts are rare neoplasms, with the majority of reported cases occurring within the hind limb muscles and soft tissues in older horses. The following article documents 21 cases of equine giant-cell tumors of soft parts clinically examined within the state of Colorado from 2000 to 2007. The majority of cases occurred in male horses aged 10 years or older. Nine (43%) arose within the hind limbs. Key histologic features included numerous multinucleated giant cells and hemosiderin-laden macrophages admixed with a spindle-cell proliferation. The majority demonstrated liposarcomatous change, variable areas of necrosis and hemorrhage, and an intermediate number of mitotic figures. Immunohistochemical results demonstrated 2 distinct cell populations: vimentin-expressing neoplastic mesenchymal cells and CD18 (histiocytic marker) expressing multinucleated giant cells. These results suggest a mesenchymal origin of the neoplasm with possible recruitment of the secondary histiocytic population. Surgical excision was attempted in the majority of horses and was considered clinically complete. A recurrence of the neoplasm was documented in 1 horse and 1 mule. In 18 horses, surgical excision, regardless of margin integrity, appeared successful with no recurrence of disease documented. Unfortunately, 10 of 21 horses were lost to follow-up within approximately 3 months of surgery. Of the 11 remaining horses that were available for follow-up evaluation, there has been no evidence of metastasis. A larger case series with more controlled follow-up is necessary to evaluate malignant potential and the importance of complete surgical excision.

show abstract

Malignant giant cell tumor of soft parts

Cited by 30 publications

References 8 publications

Giant cell tumor of soft tissue: a case report with emphasis on MR imaging

Giant cell tumor of soft tissue: a case report with emphasis on MR imaging

Giant cell tumor of the uterus: case report and response to chemotherapy

Equine Giant Cell Tumor of Soft Parts: A Series of 21 Cases (2000–2007)

Contact Info

Product

Resources

About